Vol 5, No 6 (2004): Practical Diabetology
Research paper
Published online: 2005-02-02
Continuous subcutaneous insulin infusion in preschool children with type 1 diabetes mellitus
Diabetologia Praktyczna 2004;5(6):307-310.
Abstract
INTRODUCTION. Continuous subcutaneous insulin
infusion (CSII) has been shown to be a safe and effective
method of insulin therapy in adults, adolescents
and older children with type 1 diabetes mellitus.
The aim of this study was to evaluate the results
of CSII treatment in preschool diabetic children
attending diabetes clinic in University Children Hospital
in Kraków.
MATERIAL AND METHODS. The data of 15 children (8 girls, 7 boys) were analysed, mean age at CSII initiation: 5.6 ± 1.6 years (range 2.1–7.8 years), diabetes duration: 2.3 ± 1.1 years (range: 0.8–3.9 years), median follow-up period: 27 months (19–32 months). Glycosylated haemoglobin (HbA1c) was measured at least 4 times a year by HPLC (BioRad).
RESULTS. Mean HbA1c in the year preceeding CSII initiation was 7.1 ± 0.8% and significantly decreased during the first 6 months of CSII treatment to 6.8 ± 0.7% (p < 0.05). HbA1c did not change at the further follow-up 6.7 ± 0.6% after 24 months and 6.8 ± 0.9% after 30 months in 8 kids with the longest period of CSII treatment. Mean HbA1c for all postpump visits for all children was 6.8 ± 0.7%. BMI values did not change (BMI-SDS prepump 0.77 vs. 0.63 during CSII). The total daily insulin requirement decreased from 0.75 U/kg at multiple daily injecions to 0.69 U/kg during pump therapy. The frequency of severe hypoglycemia was the same.
CONCLUSION. CSII is safe and effective method to improve metabolic control in youngest children with type 1 diabetes.
MATERIAL AND METHODS. The data of 15 children (8 girls, 7 boys) were analysed, mean age at CSII initiation: 5.6 ± 1.6 years (range 2.1–7.8 years), diabetes duration: 2.3 ± 1.1 years (range: 0.8–3.9 years), median follow-up period: 27 months (19–32 months). Glycosylated haemoglobin (HbA1c) was measured at least 4 times a year by HPLC (BioRad).
RESULTS. Mean HbA1c in the year preceeding CSII initiation was 7.1 ± 0.8% and significantly decreased during the first 6 months of CSII treatment to 6.8 ± 0.7% (p < 0.05). HbA1c did not change at the further follow-up 6.7 ± 0.6% after 24 months and 6.8 ± 0.9% after 30 months in 8 kids with the longest period of CSII treatment. Mean HbA1c for all postpump visits for all children was 6.8 ± 0.7%. BMI values did not change (BMI-SDS prepump 0.77 vs. 0.63 during CSII). The total daily insulin requirement decreased from 0.75 U/kg at multiple daily injecions to 0.69 U/kg during pump therapy. The frequency of severe hypoglycemia was the same.
CONCLUSION. CSII is safe and effective method to improve metabolic control in youngest children with type 1 diabetes.
Keywords: continuous subcutaneous insulin infusioninsulin pump therapychildrentype 1 diabetes